secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000950170-25-060085
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances
-------------------------------------------------------------------------

- First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.
- Net loss attributable to common stockholders $167.4M ($0.88 EPS) vs $35.2M ($0.20) YoY; total revenue $116.6M vs $211.1M.
- Cash $540.6M at March 31, 2025; expects $105M milestone payments in Q2 for ex-U.S. BEYONTTRA approvals.
- Phase 2 encaleret in hypoparathyroidism: 78% of 9 patients achieved normal blood & urine calcium within 5 days.
- Priced $500M 1.75% convertible notes due 2031; used $459M to repay term loan; Thomas Trimarchi appointed President/CFO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/0000950170-25-060085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-060085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer